Kannada now compulsory in all schools

Bengaluru, May 4: A total of 37 new COVID-19 cases have been reported in the last 24 hours in Karnataka taking the total number to 651, State Health Department said on Monday.

"Thirty seven new coronavirus positive cases have been confirmed in Karnataka from 5 pm yesterday to 5 pm today. The total number of cases in the state stands at 651," the department said.

The total number of cases includes 27 deaths and 321 persons who have been discharged. Of the remaining 302 cases, 296 patients are in isolation in designated hospitals and six patients are in ICU.

India has registered 2,553 new COVID-19 cases in the last 24 hours and the total number of cases now stands at 44,532.

Mangaluru, Apr 4: With the district administration formally confirming three new cases of covid-19, the total number of coronavirus positive cases in Dakshina Kannada today mounted to 12. 

A 43-year-old man from Thumbey in Bantwal taluk of Dakshina Kannada had been to Delhi on March 11 due to personal work and returned on March 22. His throat swabs were sent for testing on April 2 though he was healthy. Today the report of the test claimed that he was infected with covid-19. However, he is still said to be healthy.

In another case, a man from Udupi, who had returned from Dubai on March 21, was under medical observation after he landed at Mangaluru International Airport. The district administration today claimed that he too is suffering from the covid-19. 

A resident of Thokkottu, on February 6, had travelled to Mumbai and then visited Delhi. On March 6 he had returned to Mangaluru. On April 2, his throat swabs were sent for testing and the report today showed positive.

All three have been admitted to Wenlock Hospital for treatment.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.